⌕
NovoCure · NVCR · Nasdaq
Tenet 38 · Weak
Compare
$11.14−1.42%At closeTenet 38 · Weak
$11.14−0.16 (−1.42%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

NovoCure (NVCR) Stock

NovoCure (NVCR) closed at $11.14 on Nov 17, 2026; its Tenet Score is 38 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

21 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$11.14
Nov 17, 2026
Market cap
$1.3B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
9.82 – 21.45
low → high · as of close, Nov 16, 2026
Tenet Score
38/100
Weak · 340 Healthcare peers

Industry: Health Services

NovoCure Ltd scores 38/100. Weak. Growth is the soft spot versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
38/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
53
Quality
32
Health
41
Growth
27

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityDHealthDGrowthFMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
3.8×
Sep 30, 2026 balance sheet
P/S
1.8×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
−35%
TTM through Sep 30, 2026
Operating margin
−23.5%
fiscal 2025, before interest and tax
Net margin
−16.8%
TTM through Sep 30, 2026
Current ratio
2.49
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About NovoCure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 78 US ETFs · top wrappers by weightSee all ETFs holding NVCR →

Similar-sized companies in Health Services

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is NovoCure in?

NovoCure is in the Healthcare sector and the Health Services industry.

What is NovoCure's Tenet Score?

NovoCure's Tenet Score is 38 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.